Psychedelic therapy gains traction, attracting big Pharma due to its potential beyond depression and PTSD. Regulatory shifts, including FDA guidelines, are sparking increased investor interest in this burgeoning field.
Psychedelic therapy gains traction, attracting big Pharma due to its potential beyond depression and PTSD. Regulatory shifts, including FDA guidelines, are sparking increased investor interest in this burgeoning field.
Neurodegenerative disorders like Alzheimer’s Disease (AD), Huntington’s Disease (HD), Parkinson’s Disease (PD), and Amyotrophic Lateral Sclerosis (ALS) are intricately linked...
View Article
Unlocking Neurodegenerative Mysteries: Explore the intricate interplay of autophagy and lysosomal function in the human brain. Discover the promise and challenges in targeting these pathways for therapeutic interventions in neurodegenerative diseases.
Dive into the world of 5-HT2A receptor modulation, DMPK, and novel psychedelics. Learn how these aspects impact therapeutic responses and discover our exciting research at SfN 2023.
Alzheimer’s disease (AD) is a devastating disease for the patient, their family and friends, and also their community and wider...
View Article
The explosion of research interest, clinical development and funding of psychedelic therapeutics for disorders such as depression, PTSD and substance...
View Article
Discover effective hit identification strategies in drug discovery at Sygnature Discovery. Explore knowledge-based hit generation, High Throughput Screening (HTS), large database virtual screening, and fragment-based screening. Our expert scientists can guide your project to success.